ArticleEuropean journal of drug metabolism and pharmacokinetics2017
In Vivo Pharmacokinetics of Puerarin via Different Drug Administration Routes Based on Middle Cerebral Artery Occlusion Model.
Article in European journal of drug metabolism and pharmacokinetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 12 citations in OpenAlex.
- Puerarin Attenuates Oxidative Stress and Ferroptosis via AMPK/PGC1α/Nrf2 Pathway after Subarachnoid Hemorrhage in Rats.Antioxidants (Basel, Switzerland) · 2022Article
- Coexisting flavonoids and administration route effect on pharmacokinetics of Puerarin in MCAO rats.Open life sciences · 2020Article
- Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine.Drug delivery · 2019Review
- Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin.IBRO reports · 2019Article
- Effects of puerarin combined with conventional therapy on ischemic stroke.Experimental and therapeutic medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesPueraria labata has traditionally been applied in the treatment of stroke in Chinese clinics. Puerarin is the key ingredient in it for brain protection effect. To find a superior administration route for puerarin in the treatment of ischemic cerebrovascular disease, the pharmacokinetics of puerarin based on the middle cerebral artery occlusion (MCAO) rat via different administration routes were studied and compared.
methodsTen rats (MCAO model) divided into two groups were treated with puerarin via intravenous and intranasal routes. Samples of brain and plasma were collected by microdialysis and tested by high-performance liquid chromatography with tandem mass spectrometric detection (HPLC-MS/MS).
resultsIn olfactory bulb, the intranasal group got a higher C
conclusionsThe in vivo experiments based on the MCAO model showed that, compared with intravenous route, the bioavailability and brain-targeting of drug were highly improved via intranasal route. In pathological conditions, compared with normal rats, the AUC of puerarin in brain and DTI increased significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.